RECIST may not provide a complete assessment of immunotherapeutics

Efforts are underway to change response reporting for immunotherapies as it differs from that of the RECIST criterial.
http://accc-iclio.org/wp-content/uploads/2015/07/ICLIO-01-Webinar-irRC-Slides.pdf

What is RECIST?
RECIST (Response Evaluation Criteria In Solid Tumors) is a set of published rules that define when cancer patients improve (“respond”), stay the same (“stable”) or worsen (“progression”) during treatments.

There is a difference in response to immune related responses. The new criteria is Immune related response criterial (irRC.)